Correct Answer: B. Chemotherapy is given before radical surgery to reduce the bulk of the tumor
Neoadjuvant chemotherapy is systemic chemotherapy administered before the primary definitive surgical treatment (radical surgery) with the explicit goal of reducing tumor bulk and improving surgical resectability. In cervical cancer stage 2A, the tumor extends beyond the cervix but remains confined to the pelvis without distant metastases. Neoadjuvant chemotherapy shrinks the primary tumor and any regional lymph node involvement, thereby converting an initially unresectable or marginally resectable tumor into one amenable to complete surgical excision with negative margins. This approach improves overall survival and reduces local recurrence rates compared to surgery alone. The chemotherapy regimen typically used in Indian practice for cervical cancer is platinum-based (cisplatin-paclitaxel or cisplatin-5FU), as per NCCN and Indian oncology guidelines. After completion of neoadjuvant chemotherapy (usually 2–3 cycles), the patient undergoes radical hysterectomy with pelvic lymphadenectomy. This sequencing allows the surgeon to achieve better disease control while preserving functional outcomes where possible.
Why the other options are wrong
A. Chemotherapy is given along with radiation. — This describes concurrent chemoradiation, not neoadjuvant chemotherapy. Concurrent chemoradiation is indeed used in cervical cancer (especially stages IB–IVA), but it is not neoadjuvant—it is primary definitive treatment. Neoadjuvant implies chemotherapy precedes the main modality (surgery in this case). This option confuses two distinct treatment paradigms. C. Chemotherapy is given during surgery. — This is not a recognized oncologic term or practice. Chemotherapy cannot be meaningfully administered intraoperatively; it requires systemic circulation and time to exert cytotoxic effects. This is a distractor that conflates timing with the surgical procedure itself, testing whether students understand the temporal sequence of cancer treatment modalities. D. Chemotherapy is given after radical surgery for micrometastases. — This describes adjuvant chemotherapy, not neoadjuvant. Adjuvant therapy is given after surgery to eliminate residual micrometastatic disease. While adjuvant chemotherapy is also used in cervical cancer, it is fundamentally different from neoadjuvant therapy in timing and intent. NBE tests whether students can distinguish these two critical sequencing concepts.
High-Yield Facts
- Neoadjuvant chemotherapy = systemic chemotherapy before primary definitive treatment (surgery/radiation) to reduce tumor bulk and improve resectability.
- Adjuvant chemotherapy = systemic chemotherapy after primary treatment to eliminate micrometastatic disease; opposite timing and intent from neoadjuvant.
- Cervical cancer stage 2A = tumor extends beyond cervix into parametrium but not to pelvic sidewall; candidate for neoadjuvant chemotherapy followed by radical hysterectomy.
- Platinum-based regimens (cisplatin-paclitaxel, cisplatin-5FU) are standard neoadjuvant agents in Indian cervical cancer practice per NCCN and IAP guidelines.
- Concurrent chemoradiation (not neoadjuvant) is primary definitive treatment for stages IB–IVA cervical cancer; neoadjuvant is used when surgery is planned as the main modality.
Mnemonics
NAC vs ADJ (Timing & Intent) NAC = Before (Neo = new/before) + goal is Reduce bulk for better surgery. ADJ = After + goal is Kill micrometastases. Use: When asked about chemotherapy sequencing in cancer, always ask 'Is it before or after surgery?' NACO (Neoadjuvant Chemotherapy Oncology) Neoadjuvant = Not yet operated. Adjuvant = After operation. Use: Quick recall when distinguishing pre-operative vs post-operative chemotherapy.
NBE Trap
NBE pairs "chemotherapy" with "radiation" in option A to trap students who conflate concurrent chemoradiation (a valid primary treatment for cervical cancer) with neoadjuvant therapy. The key discriminator is timing: neoadjuvant precedes surgery; concurrent chemoradiation is the primary definitive treatment, not a precursor to surgery.
Clinical Pearl
In Indian tertiary cancer centers, neoadjuvant chemotherapy for stage 2A cervical cancer improves surgical outcomes by converting borderline-resectable tumors into fully resectable ones, reducing operative morbidity and improving disease-free survival—a key advantage in resource-limited settings where adjuvant radiation may not always be accessible.
_Reference: Bailey & Love Ch. 74 (Gynaecological Oncology); Harrison Ch. 105 (Cervical Cancer Management)_